Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02690207 · ClinicalTrials.gov registry record · Phase 3

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

A Phase 3 study of Herpes Zoster, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
8,687
Enrollment target
20
Study locations

NCT02690207 is a Phase 3 study of Herpes Zoster that has completed, run by GlaxoSmithKline. The registered enrollment target is 8,687 participants, above the 1,631-participant average among 16 other Herpes Zoster trials with a reported enrollment target (433% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02690207, a Phase 3 study of Herpes Zoster, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
8,687 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects \>= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229).

Conditions Studied

Herpes Zoster

Interventions

  • BIOLOGICAL Herpes Zoster Vaccine GSK1437173A

Study Locations (20)

Arizona

  • GSK Investigational Site - Mesa
  • GSK Investigational Site - Phoenix
  • GSK Investigational Site - Phoenix
  • GSK Investigational Site - Phoenix
  • GSK Investigational Site - Tucson

Florida

  • GSK Investigational Site - Clearwater
  • GSK Investigational Site - DeLand
  • GSK Investigational Site - Jacksonville
  • GSK Investigational Site - Jacksonville
  • GSK Investigational Site - West Palm Beach

Maryland

  • GSK Investigational Site - Columbia
  • GSK Investigational Site - Elkridge

North Carolina

  • GSK Investigational Site - Cary
  • GSK Investigational Site - Charlotte

California

  • GSK Investigational Site - Spring Valley

Idaho

  • GSK Investigational Site - Meridian

Kansas

  • GSK Investigational Site - Wichita

Missouri

  • GSK Investigational Site - Kansas City

Trial Details

FieldValue
Enrollment Target 8,687 participants
Start Date 2016-03-16
Est. Completion 2019-03-15
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02690207

The ClinicalTrials.gov registry entry for NCT02690207 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8,687 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,631-participant average among 16 other Herpes Zoster trials with a reported enrollment target (433% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 1 intervention - of which Herpes Zoster Vaccine GSK1437173A is the first listed.

NCT02690207 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Arizona, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT02690207 about?

NCT02690207 is a clinical study titled "Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.". The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects \>= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) and ZOS...

What is the current status of trial NCT02690207?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,687 participants. The study started on 2016-03-16. Estimated completion is 2019-03-15.

What conditions does trial NCT02690207 study?

This clinical trial studies the following conditions: Herpes Zoster.

What interventions are being tested in trial NCT02690207?

The interventions under investigation include: Herpes Zoster Vaccine GSK1437173A (BIOLOGICAL).

Who is sponsoring clinical trial NCT02690207?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02690207 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Idaho, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Herpes Zoster

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Herpes Zoster

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.